GamaMabs Pharma doses first patient in Phase ll trial of GM102

18th September 2018 (Last Updated September 18th, 2018 00:00)

GamaMabs Pharma has dosed the first patient in its Phase ll clinical trial of GM102 and in combination with Trifluridine/Tipiracil (Lonsurf) to treat patients with advanced or metastatic colorectal cancer (CRC).

GamaMabs Pharma doses first patient in Phase ll trial of GM102
Histopathologic image of colonic carcinoid stained by haematoxylin and eosin. Credit: KGH.

GamaMabs Pharma has dosed the first patient in its Phase ll clinical trial of GM102 and in combination with Trifluridine/Tipiracil (Lonsurf) to treat patients with advanced or metastatic colorectal cancer (CRC).

The European multicentre, two-parallel, non-randomised trial aims to enrol two cohorts of patients.

Cohort one will include patients who have progressed after at least two lines of prior systemic therapies for metastatic or locally advanced disease and have received all prior available therapies, while the cohort two will include subjects to administer Lonsurf.

The trial will evaluate objective response rates, immunological changes in the tumour microenvironment, progression-free and overall survival rates of the enrolled patients.

It is based on results of collaborative research with various European academic research centres and hospitals.

"The C201 study will investigate the anti-tumour activity of GM102 in this new indication and its potential synergism with Lonsurf for patients who have progressed on prior therapies."

The results showed various Anti-Mullerian hormone receptor type 2 (AMHRII) expression in human CRC tumours and a significant expression of the target on tumour cells at the membrane level.

GamaMabs Pharma chief medical officer Isabelle Tabah-Fisch said: “The C201 study will investigate the anti-tumour activity of GM102 in this new indication and its potential synergism with Lonsurf for patients who have progressed on prior therapies.

“Most CRC tumours express moderate-to-large macrophage infiltration. GM102 therefore has a potential to enhance macrophage phagocytosis on tumour cells in addition to acting synergistically with Lonsurf.

“This is a key step in the development of our molecule, which has already shown excellent tolerability in patients with gynecological cancers and first signs of activity in the first patients in the phase la/lb C101 study, recently presented at the ASCO 2018 conference.”

GM102 is a glyco-engineered (low-fucose) monoclonal antibody designed to target tumour antigen AMHRII, which is re-expressed in around 70% of CRC patients.